Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2006-03-28
2006-03-28
Naff, David M. (Department: 1651)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C424S486000, C514S002600, C514S773000
Reexamination Certificate
active
07018654
ABSTRACT:
A method of protecting a chemical compound from degradation comprising combining the chemical compound with an amino acid polymer. Disclosed are methods of combining chemical compounds with synthetic amino acid polymers for protection from degradation of the chemical compounds and to provide for controlled release of the compounds. A method is described for the selective release of drug substances from a synthetic amino acid polymer in the stomach or small intestine, utilizing pH-dependent changes in a higher order structure. A pharmaceutical composition comprising a drug substance that has been combined with an amino acid polymer and a pharmaceutically acceptable combination of excipients is disclosed. A cell culture media comprising a polypeptide containing glutamine that has been co-polymerized with an amino acid is described.
REFERENCES:
patent: 3331814 (1967-07-01), Randall
patent: 3846399 (1974-11-01), Hirschmann et al.
patent: 3975342 (1976-08-01), Gross
patent: 4040907 (1977-08-01), Ullman et al.
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4483807 (1984-11-01), Asano
patent: 4552864 (1985-11-01), Antoni et al.
patent: 4569844 (1986-02-01), Jones
patent: 4657873 (1987-04-01), Gadow
patent: 4753804 (1988-06-01), Iaccheri
patent: 4863735 (1989-09-01), Kohn et al.
patent: 4925673 (1990-05-01), Steiner
patent: 4960790 (1990-10-01), Stella et al.
patent: 4976962 (1990-12-01), Bichon et al.
patent: 5057317 (1991-10-01), Iida
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5234696 (1993-08-01), Van Scoik
patent: 5238714 (1993-08-01), Wallace et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5451410 (1995-09-01), Milstein
patent: 5534496 (1996-07-01), Lee et al.
patent: 5643957 (1997-07-01), Leone-Bay
patent: 5681748 (1997-10-01), DiSorbo
patent: 5741705 (1998-04-01), Blom
patent: 5756291 (1998-05-01), Griffin
patent: 5762909 (1998-06-01), Uzgiris
patent: 5767227 (1998-06-01), Latham et al.
patent: 5776885 (1998-07-01), Orsolini
patent: 5792451 (1998-08-01), Sarubbi
patent: 5820881 (1998-10-01), Milstein
patent: 5846743 (1998-12-01), Janmey et al.
patent: 5851536 (1998-12-01), Yager et al.
patent: 5861387 (1999-01-01), Labrie
patent: 5882645 (1999-03-01), Toth et al.
patent: 5891478 (1999-04-01), Johnson
patent: 5898033 (1999-04-01), Swadesh et al.
patent: 5910569 (1999-06-01), Latham et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5952294 (1999-09-01), Lazo et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6458842 (2002-10-01), Dickinson et al.
patent: 0 187 547 (1986-07-01), None
patent: 2 533 222 (1984-03-01), None
patent: 52100486 (1977-08-01), None
patent: 55145736 (1980-11-01), None
patent: 04126160 (1992-04-01), None
patent: WO 95/12605 (1995-05-01), None
patent: WO 95/14033 (1995-05-01), None
patent: WO 97/36616 (1997-10-01), None
Orten, James M. et al., “Thyroxine,”Human Biochemistry, 9thEd., C.V. Mosby Company, St. Louis,pp. 401-405 (1975).
Li, Chun, et al., “Complete Regression of Well-Established Tumors Using a Novel Water-Soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate,”Cancer Res, 58:2404-2409 (1998).
Kramer, Werner et al., “Intestinal Absorption of Peptides by Coupling to Bile Acids,”The Journal of Biochemistry, 269(14):10621-10627 (1994).
Rawitch, Allen B., et al., “The Isolation of Identical Thyroxine Containing Amino Acid Sequences from Bovine, Ovine and Porcine Thyroglobulins,”Biochemical and Biophysical Research Communications, 118(2):423-429 (1984).
Marriq, Claudine, et al., “Amino Acid Sequence of the Unique 3,5,3′-Triodothyronine-Containing Sequence from Porcine Thyroglobulin,”Biochemical and Biophysical Research Communications, 112(1):206-213 (1983).
Sawada, Kyoko, et al., “Recognition of L-Amino Acid Ester Compounds by Rat Peptide Transporters PEPT1 and PEPT2,”Journal of Pharmacology and Experimental Therapeutics, 291(2):705-709 (1999).
De Vrueh, Remco L.A., et al, “Transport of L-Valine-Acyclovir Via the Oligopeptide Transporter in the Human Intestinal Cell Line, Caco-2,”Journal of Pharmacology and Experimental Therapeutics, 286(2):1166-1170 (1988).
Guo, Ailan, et al., “Interactions of a Nonpeptide Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Journal of Pharmacology and Experimental Therapeutics, 289(1):448-454 (1999).
Burnette, Thimysta C., et al., “Metabolic Disposition of the Acyclovir Prodrug Valaciclovir in the Rat,”Drug Metabolism and Disposition, 22(1):60-64 (1994).
Aggarwal, et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine,”J. Med. Chem., 33(5):1505-1511 (1990).
Zunino, Franco, et al., “Comparison of Antitumor Effects of Daunorubicin Covalently Linked to Poly-L-Amino Acid Carriers,”European Journal of Cancer&Clinical Oncology, 20(3):121-125 (1984).
Havranova, Marie et al., “A High-Molecular Mass Derivative of Trypsin-Kallikrein Inhibitor for Potential Medical Use, II,”Hoppe-Seyler's Z. Physiol. Chem., 363:295-303 (1982).
Ryser, Hugues J.P., et al., “Conjugation of Methotrexate to Poly (L-lysine) increases Drug Transport and Overcomes Drug Resistance in Cultured Cells,”Proc. Natl. Acad. Sci. USA, 75(8):3867-3870 (1978).
Han, Hyo-Kyung, et al., “Targeted Prodrug Design to Optimize Drug Delivery,”AAPS PharmSci, 2(1): Article 6 (2000).
Tamai, I., et al., “Improvement of L-dopa Absorption by Dipeptidyl Derivation, Utilizing Peptide Transporter PepT1,”J. Pharma. Sci., 87(12):1542-1546 (1988), Abstract.
Oh, D.M., et al., “Drug Transport and Targeting. Intestinal Transport,”Pharma Biotechnol, 12:59-88 (1999), Abstract.
Balimane, P., et al., “Effect of Ionization on the Variable Uptake of Valacyclovir via the Human Intestinal Peptide Transporter (hPepT1) in CHP cells,”Biopharm Drug Dispos, 21(5):165-174 (2000), Abstract.
Knutter, I, et al., “A Novel Inhibitor of the Mammalian Peptide Transporter PEPT1,”Biochemistry, 40(14):4454-4458 (2001), Abstract.
Shen, H., et al., “Developmental Expression of PEPT1 and PEPT2 In Rat Small Intestine, Colon, and Kidney,”Pediatr Res, 49(6):789-795 (2001), Abstract.
Friedrichsen, G.M., et al., “Model Prodrugs Designed for the Intestinal Peptide Transporter. A Synthetic Approach for Coupling of Hydroxy-Containing Compounds to Dipeptides,”Eur J Pharm Sci, 14(1):13-19 (2001, Abstract.
Han H., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT and Absorbed by the Intestinal PEPT1 Peotide Transporter,”Pharm Res, 15(8):1154-1159 (1998), Abstract.
Blimane, P.V., et al., “Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug. Valacyclovir,”Biochem Biophys Res Commun, 250(2):246-251 (1998), Abstract.
Han, H.K., et al., “Cellular Uptake Mechanism of Amino Acid Ester prodrugs in Caco-2hPEPT1 Cells Overexpressing a Human Peptide Transporter,”Pharm Res, 15(9):1382-1386 (1998), Abstract.
Shiraga, T., et al., “Cellular and Molecular Mechanisms of Dietary Regulation on Rat Intestinal H+/Peptide Transporter PepT1,”Gastroenterology, 116(2):354-362 (1999), Abstract.
Guo, A., et al., “Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line,”Pharmacol Exp Ther, 289(1):448-454 (1999), Abstract.
Amidon, G.L., et al., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT are Absorbed by the Intestinal PEPT1 Peptide Transporter,”Pharm Res, 16(2):175 (1999), Abstract.
Kirk Randal J.
Latham Keith R.
Hunton & Williams LLP
Naff David M.
New River Pharmaceuticals Inc.
Ware Deborah K.
LandOfFree
Pharmaceutical composition containing an active agent in an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition containing an active agent in an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition containing an active agent in an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3580455